Altogether, the present study underlines a complex mechanism of action of a novel and selective ROCK2 inhibitor that concurrently targets adaptive and innate immune cells as well as adipocytes and fibroblasts, achieving potent anti-inflammatory and anti-fibrotic effects, enabling efficient treatment of established liver fibrosis. Here, ROCK2 is linked to Hepatic fibrosis.